On The Pen GLP-1 News
Episodes
GLP-1 Coverage Is COLLAPSING in 2027
Host Dave Knapp discusses the shrinking access to GLP-1 medications as employers and states pull back coverage due to costs.
$50 Zepbound Incoming? China Has US in a GLP-1 “Chokehold”
Host Dave Knapp discusses Andrew Dudham’s prediction that GLP-1 prices could drop to $40–$50 monthly, driven by competition and compounding.
200 GLP-1 Deaths, Chrissy Metz & a Stunning Harvard Study
Host Dave Knapp contextualizes reports of over 200 UK deaths linked to GLP-1s, analyzing the tragic case of 19-year-old Josephine Nassar to distinguish correlation from causation.
Eli Lilly Earnings Call Recap: Retatrutide News
Host Dave Knapp analyzes Eli Lilly’s Q2 2026 earnings, focusing on the company’s push to classify retatrutide as a biologic to protect market dominance.
Novo Nordisk Warned us For Years About Synthesized Semaglutide. Now They Want In.
Host Dave Knapp discusses Novo Nordisk’s potential shift toward synthetic semaglutide production in China, contrasting this with their years of anti-compounding rhetoric.
Retatrutide Biologic Battle: The Story Gets Bigger
Host Dave Knapp analyzes the Eli Lilly vs.
GLP-1 Showdown: Inside The High Stakes War over Patients
Medicare, New Drugs, and a Surprising GLP-1 Trend, What Patients Need to Know
Host Dave Knapp analyzes new data showing many patients restart GLP-1s after stopping, arguing that systemic barriers like insurance, not patient failure, drive discontinuation.